mTORC1 prevents preosteoblast differentiation through the notch signalling pathway  by Huang, Bin et al.
Session: Disease & Treatment 93group; Group 3: OA Group. In group 2e3, osteoarthritis was induced in the right
knee joint with ACLT+MMx in rats. Group 2 received continuous infusion of the gin-
senoside Rb1 via an osmotic mini-pump, implanted subcutaneously. At four weeks
after treatment, the rat was sacrificed. Interleukin-1 beta (IL-1b) level was evalu-
ated by ELISA; cartilage damage was assessed via histology (Safranin-O/fast green
stain) and immunohistochemistry (MMP13, Col X). In the cell study, C5.18 (Rat
chondrocyte cell line) was used. The effect on Rb1 of IL-1b- induced MMP13 or
Col X expression level in C5.18 cells was investigated.
Results: In the in vivo study, characteristics of OAwere present in the OA group, con-
trary to the Rb1 treatment group where, in general, less severe damage occurred:
initially, IL-1b level was significantly decreased; then, cartilage degeneration was
attenuated, by lower histologic damage scores and the percentage of MMP13 or
Col X positive chondrocytes. In the cell study, the results showed that Rb1treatment
would relieve the MMP13 or Col X expression in C5.18 cells in IL-1b induction.
Conclusion: In the present study, we demonstrated that Rb1 can attenuate the
progression or severity of arthritis via reducing the inflammation level.
http://dx.doi.org/10.1016/j.jot.2016.06.076163
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Background: Recent studies suggest association between ABO blood group and
inflammation, which was crucial in the pathological process of primary knee oste-
oarthritis. This study was aimed to investigate whether ABO blood group was asso-
ciated with primary knee osteoarthritis.
Methods: We performed a retrospective review of patients of primary knee oste-
oarthritis as the case group, and a random sampling of healthy blood donors as the
control group. The severity of knee osteoarthritis at the first outpatient visit was
evaluated by the Kellgren/Lawrence scoring system. Further study was performed
to investigate the expression of blood group antigens in synovial tissue of the knee
in both cases and controls.
Results: 1126 cases and 30299 controls were involved. Logistic regression revealed
that AB blood group was a risk factor of primary knee osteoarthritis (PZ0.025 and
0.048 for univariate and multivariate analysis, respectively), independent of age
(PZ0.973) and sex (PZ0.520). Patients of blood group AB had a higher K/L score
(PZ0.017). Immunohistochemical study indicated association between LeY antigen
and primary knee osteoarthritis (PZ0.029).
Discussions and Conclusions: This study suggested that blood group AB was asso-
ciated with primary knee osteoarthritis, as well as its radiological severity. Further
study indicated that LeY antigen, which was related to blood group, was associated
with primary knee osteoarthritis.
http://dx.doi.org/10.1016/j.jot.2016.06.077169
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Introduction: Disruption of the balance between bone formation and resorption
results in loss of bone mass and causes bone diseases such as osteoporosis. Current
therapies for osteoporosis are limited to antiresorptive agents, while bone diseases
due to reduced osteoblast activity, such as senile osteoporosis, urgently require
targeted treatment and novel strategies to promote bone formation. mTORC1
has emerged as a critical regulator of bone formation and is therefore a potential
target in the development of novel bone-promoting therapeutics. Identifying the
detailed function of mTORC1 in bone formation and clarifying the underlying
mechanisms may uncover useful therapeutic targets.
Subjects and Methods: We treated osteoblasts and mice with rapamycin (the
mTORC1-specific inhibitor) and established conditional Tsc1 knockout cell and
mouse models (with activated mTORC1). We detected the proliferation rate and
differentiation potential of osteoblasts with impaired or activated mTORC1 and
explored the regulatory mechanism responsible.
Results: mTORC1 is activated during preosteoblast proliferation but is suppressed
during their differentiation. Inactivation of mTORC1 prevents preosteoblast prolif-
eration but enhances their differentiation in vitro and in vivo. mTORC1 activation
in preosteoblasts produces immature woven bone in mice due to excess prolifera-
tion and impaired differentiation. mTORC1 inhibits Runx2 expression by activating
Notch signalling in preosteoblasts. Preosteoblasts with hyperactive mTORC1 re-ac-
quired the capacity to fully differentiate and mature when subjected to inhibition
of the Notch pathway.Discussion and Conclusions: mTORC1 signalling has emerged as a critical regulator
of bone formation; however, results from in vitro and in vivo studies on the func-
tion of mTORC1 in osteoblast lineage are inconsistent. Using mTORC1 specific in-
hibitor and conditional knockout cell and mouse models, we elucidated the role
of mTORC1 in osteoblast formation. Here, we report that activation of mTORC1
is required for preosteoblast proliferation; however, inactivation of mTORC1 is
essential for their differentiation and maturation. Mechanistically, mTORC1 pre-
vented osteoblast maturation through activation of the STAT3/p63/Jagged/Notch
pathway and down-regulation of Runx2. In conclusion, this study clarified the po-
tential role of mTORC1 signalling in the regulation of preosteoblast proliferation
and differentiation and identified Notch signalling and Runx2 as critical down-
stream mediators. Pharmaceutical coordination of the pathways and agents in pre-
osteoblasts may be beneficial in bone formation.
http://dx.doi.org/10.1016/j.jot.2016.06.078174
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Introduction: Previously, we reported that sufficient lymphatic drainage was
favourable for the treatment of Rheumatoid arthritis (RA) and treatment targeting
joint lymphatic drainage function contributed to the improvement of chronic
inflammation of joints. JuanBi Tang (JBT), a Chinese patent medicine, has been
widely used for the treatment of RA in China, which can relieve symptoms of
arthritis and activate joint function of patients. The aim of this study is to inves-
tigate whether JBT could attenuate inflammation and promote lymphatic drainage
function and lymphangiogenesis of TNF-Tg mice.
Subjects and Methods: Three-month old TNF-Tg mice and WT littermates were
used. (1) The effect of JBTon lymphatic drainage function was detected with Indoc-
yanine green near-infrared (ICG-NIR) lymphatic imaging system. (2) The effect of
JBT on ankle joints inflammation were assessed by haematoxylin and eosin (H&E)
staining, Alcian blue/orange G (ABHO) staining, and tartrate resistant acid phospha-
tase (TRAP) staining. (3) The effect of JBT on lymphangiogenesis at inflammatory
ankle joints was detected by using anti-LYVE-1 and anti-podoplanin antibodies for
double immunofluorescence staining. (4) The effect of JBT on lymphangiogenesis
was determined by a zebrafish screening system. (5) The effect of JBT on iNOS
expression andNOproduction of lymphatic endothelial cells (LECs)were also tested.
Results: Decreased clearance and pulse from ICG-NIR detection indicated TNF-tg
mice lymph function is impaired, but it was rescued by JBT (p<0.05). According
to HE staining of ankle sections, JBT (1.2kg/L) could increase TNF-tg mice astraga-
lus bone area (1.540.78mm2) in contrast to saline mice (0.750.24 mm2,
p<0.05), almost equal to WT mice (1.580.75 mm2, p>0.05). The inflammation
area around the astragalus bone of TNF-tg mice (1.070.44 mm2) increased
compared with the WT littermates (0, p < 0.05). JBT could reduce the inflamma-
tion area (1.770.44mm2, p<0.05). As to Alcian blue/orange G (ABHO) stain, carti-
lage area of the astragalus bone (1.770.44mm2, p<0.05) increased more than 20-
fold in the JBT group compared with the saline group. JBT promotes lymphangio-
genesis in the ankle joint of TNF-Tg mice. JBT could also promote the formation of
the lymphatic thoracic duct of zebrafish (48h and 72h, p<0.05). In addition, JBT
blocked iNOS expression and NO production of LECs.
Conclusion: JBT decreases synovial inflammation, bone erosion and cartilage
erosion, and promotes lymphatic drainage function and lymphangiogenesis in
TNF-Tg mice. JBT is a promising agent for treating Rheumatoid arthritis and pro-
moting the lymphatic drainage function might be one of its mechanisms.
http://dx.doi.org/10.1016/j.jot.2016.06.079228
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Objective: Bone fracture non-union is a major clinical challenge in orthopaedic
practice. In addition to surgical intervention and autologous bone grafts, bone
